IP armamentarium

With the most stocked clinical pipeline among its RNAi peers, Alnylam Pharmaceuticals Inc. has made the leap from platform to products, building on an IP position that has enabled revenue-generating deals that footed the bill for optimizing drug delivery and advancing its internal pipeline.

Now, with three programs in the clinic and a fourth expected to start Phase I this year, Alnylam is on track to meet its goal of five programs in Phase III by 2015...